West Palm Beach & Sunrise Florida. ComVest NationsHealth Holdings, LLC, a wholly owned subsidiary of ComVest Investment Partners III, L.P., announced today that has it completed its previously announced acquisition of NationsHealth, Inc. (OTCBB:NHRX – News).

In connection with the closing of the transaction, ComVest made a $5.0 million investment in NationsHealth in the form of convertible preferred stock at $0.12 per share, the proceeds of which will be used by NationsHealth for general working capital purposes. In addition, ComVest has the right to make an additional $2.0 million investment in NationsHealth convertible preferred stock at $0.12 per share for a period of one year following the closing date. On April 30, 2009, upon the signing of the definitive agreement, ComVest provided NationsHealth a bridge loan in the principal amount of $3.0 million, which converted into additional shares of NationsHealth convertible preferred stock at $0.12 per share upon closing.

“I am excited to welcome NationsHealth into the ComVest portfolio of companies,” commented Michael S. Falk, ComVest’s Chairman. “We look forward to NationsHealth, and its CEO, Dr. Glenn Parker, using the additional capital to execute upon strategic initiatives and accomplish long-term plans and produce great partnerships with its customers, suppliers and employees.”

In connection with the transaction, NationsHealth entered into amendments with its credit facility lender and subordinated note holder, pursuant to which both debt facilities will remain in existence on substantially similar terms and conditions following the closing.

About ComVest:
The ComVest Group is a leading private investment firm focused on providing debt and equity solutions to middle-market companies with enterprise values of up to $250 million. Since 1988, ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through its extensive financial resources and broad network of industry experts, ComVest is able to offer its companies total financial sponsorship, critical strategic support and business development assistance.

About NationsHealth, Inc.
NationsHealth seeks to improve the delivery of healthcare to Medicare and managed care beneficiaries by providing medical products and prescription related services. NationsHealth provides home delivery of diabetes supplies and insulin pumps, medications and other medical products to patients across the nation. In addition to its medical products business, NationsHealth also provides education, marketing, enrollment and member service to insurers offering Medicare Part D prescription drug plans and other Medicare insurance coverage. NationsHealth has an agreement with CIGNA to service its Medicare Part D prescription drug plans nationally. For more information, please visit http://www.nationshealth.com

Sunrise Florida, NationsHealth, Inc. (“NationsHealth”) announced today that it has entered into a definitive merger agreement pursuant to which NationsHealth shall be acquired and taken private by ComVest NationsHealth Holdings, LLC, a wholly-owned subsidiary of ComVest Investment Partners III, L.P. (collectively, “ComVest”), a Florida-based private equity firm. Under the terms of the definitive merger agreement, ComVest will acquire all issued and outstanding shares of common stock of NationsHealth for $0.12 per share in cash, other than certain stockholders and members of NationsHealth management. The proposed transaction is expected to close by the third quarter of 2009.

Glenn Parker, MD, chief executive officer of NationsHealth, said, “This proposed transaction provides NationsHealth the additional capital needed to execute upon its strategic initiatives. Upon completion of the transaction, NationsHealth will become a private company that will provide us greater flexibility to accomplish our long-term plans, and produce a better partnership with our customers, suppliers and employees.”

In connection with the transaction, NationsHealth entered into amendments with its credit facility lender and subordinated note holder, pursuant to which both debt facilities will remain in existence on substantially similar terms and conditions following the closing of the transactions contemplated under the definitive merger agreement. Concurrently with the execution of the definitive merger agreement, ComVest has provided NationsHealth a bridge loan in the principal amount of $3.0 million, which will convert into shares of NationsHealth convertible preferred stock at $0.12 per share upon closing of the transaction. ComVest will make an additional $5.0 million investment in NationsHealth at closing in the form of NationsHealth convertible preferred stock at $0.12 per share, the proceeds of which will be used to take NationsHealth private and for general working capital purposes. In addition, ComVest shall have the right to make an additional $2.0 million investment in NationsHealth convertible preferred stock at $0.12 per share for a period of one year following the closing date.

A Special Committee of independent directors and the NationsHealth Board of Directors have approved the definitive merger agreement and recommended to the NationsHealth stockholders that they approve the definitive merger agreement. The NationsHealth Board of Directors, in conjunction with the Special Committee, has carefully considered this offer with the counsel of independent legal and financial advisors and, after extensive negotiations, concluded that this transaction is in the best interest of NationsHealth’s stockholders. The transaction, which is expected to close by the third quarter of 2009, is subject to approval by NationsHealth’s stockholders, as well as other customary closing conditions. Additionally, stockholders representing over 50% of the issued and outstanding shares of common stock of NationsHealth have entered into a voting agreement in favor of the merger.

Deloitte & Touche Corporate Finance LLC is acting as financial advisor to NationsHealth. Ladenburg Thalmann & Co. Inc. has rendered a fairness opinion in connection with the merger transaction to NationsHealth’s Special Committee. Legal counsel to NationsHealth’s Special Committee is Broad and Cassel.

Legal counsel to NationsHealth and its Board of Directors is McDermott Will & Emery LLP. Legal counsel to ComVest is Foley & Lardner LLP.

About NationsHealth, Inc.
NationsHealth seeks to improve the delivery of healthcare to Medicare and managed care beneficiaries by providing medical products and prescription related services. NationsHealth provides home delivery of diabetes supplies and insulin pumps, medications and other medical products to patients across the nation. In addition to its medical products business, NationsHealth also provides education, marketing, enrollment and member service to insurers offering Medicare Part D prescription drug plans and other Medicare insurance coverage. NationsHealth has an agreement with CIGNA to service its Medicare Part D prescription drug plans nationally. For more information, please visit http://www.nationshealth.com.

About ComVest:
The ComVest Group is a leading private investment firm focused on providing debt and equity solutions to middle-market companies with enterprise values of less than $250 million. Since 1988, ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through its extensive financial resources and broad network of industry experts, ComVest is able to offer its companies total financial sponsorship, critical strategic support and business development assistance

Quincy, Mass. Pipeline Data, a provider of payment processing and services, today announced that it has entered into restructuring agreements with its convertible noteholders, as well as with the holders of a $16 million put claim against the Company. The transaction was led by The ComVest Group (“ComVest”).

Under the terms of the transaction, the current $37 million, 8% coupon preferred convertible notes due June 29, 2010 will be restructured as a $42.1 million loan, 10% coupon until June 30, 2010 and a 14% coupon until June 30, 2011. The Company will have the option to extend the notes for an additional year until June 30, 2012, at its sole discretion. The agreement calls for the removal of all convertible equity features and the immediate termination of 11.1 million detached full-ratchet warrants.

In addition, the $16 million, 18% put right held by the former owners of Charge.com, Inc. will be redeemed for $2 million in cash, the return of the Charge.com name and the return of 9,398,058 shares of the Company’s Common Stock.

ComVest Investment Partners III, an affiliate of the ComVest Group, will lead a $15 million initial investment in cash for the purposes of restructuring the balance sheet and acquiring new merchant account portfolios and other operating companies. As part of the investment, the Company shall issue ComVest a $15 million face amount preferred convertible stock instrument convertible into common stock of the Company at 12.2 cents per share with a 16% payment-in-kind (PIK). Total shares outstanding post transaction will be approximately 41 million common and 122,950,820 preferred convertible shares (initially convertible into 68% of the Company’s Common Stock). Total debt will be reduced from $53 million to $42 million when taking into consideration the current combined $37 million convertible notes and the $16 million extinguishment of the put obligation. ComVest will also make available to the Company an additional $15 million acquisition line of credit, maturing September 30, 2012.

Concurrent with the transaction, Pipeline’s entire Board of Directors will resign and a new Board will be formed, including ComVest Partner and Advisory Board Member Peter J. Kight. With more than 25 years of experience, Mr. Kight is a pioneer in the electronic commerce industry, including serving as founder and former chairman of the board and CEO of CheckFree. He currently serves as the Vice Chairman and member of the board of directors of Fiserv (NASDAQ:FISV – News). Mr. Kight joined Fiserv when the company acquired CheckFree in 2007 for $4.4 billion in cash. In addition, Mr. Kight is a member of the board of directors of Akamai Technologies (NASDAQ:AKAM – News) and Manhattan Associates (NASDAQ: MANH – News). Accompanying Mr. Kight to the Pipeline Board of Directors will be Randall McCoy. Mr. McCoy served as CheckFree’s executive vice president and chief technology officer and will become Pipeline’s new Chief Executive Officer and a member of the Board. Mr. McCoy has also enjoyed a long and distinguished career in the electronic payments industry. He lectures annually to the Federal Reserve’s Board of Governors on matters of electronic commerce. Daniel Nenadovic, a Managing Director and Partner of ComVest will join the Company’s Board of Directors and serve as Chairman of the Board. MacAllister Smith , the Company’s current founder and Chief Executive Officer, will resign as Chief Executive Officer and assume the position of Vice Chairman of the Company.

MacAllister Smith stated, “While it has been a challenging time in the financial markets in general, and in the financial services sector in particular, I believe there are excellent opportunities to increase market share for strong, well-capitalized companies that focus on their core competencies. The restructuring of our debt from a 2010 maturity to as long as a 2012 maturity removes a substantial amount of near term risk, while the infusion of new cash capital allows Pipeline to take advantage of strategic acquisition and marketing opportunities as they present themselves. I am very excited about the appointments of Pete Kight to our Board and Randy McCoy as new CEO, and believe their extensive experience in the industry will open many vistas for Pipeline. In addition, ComVest brings a multitude of market knowledge, expertise and deal flow that will further strengthen Pipeline and help the Company to achieve its objectives. I am very much looking forward to working with Randy, Pete and the ComVest team and believe their proven, dynamic business strengths will help to make Pipeline a leader in the payments processing sector.”

About Pipeline Data:
Pipeline Data Inc. provides value-added credit card transaction processing services for merchants in three key areas: wireless mobile payment, e-commerce solutions and retail merchant payment.

About ComVest:
The ComVest Group is a leading private investment firm focused on providing debt and equity solutions to middle-market companies with enterprise values of less than $250 million. Since 1988, ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through its extensive financial resources and broad network of industry experts, ComVest is able to offer its companies total financial sponsorship, critical strategic support and business development assistance.

Safe Harbor Statement:

The information provided for in this Press Release contains forward-looking statements that involve risks and uncertainties more fully set forth in the Company’s filing. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to uncertainties that could affect performance and results of the Company in the future and, accordingly, such performance and results may materially differ from those expressed or implied in any forward-looking statements made by or on behalf of the Company. These risks and uncertainties include, but are not limited to those relating to the Company’s growth strategy, customer concentration, outstanding indebtedness, seasonality, expansion and other activities of competitors, changes in federal or state laws and the administration of such laws, protection of the securities markets and other risks detailed in the Company’s filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Statements made in this Press Release that are not historical facts are forward-looking statements that are subject to the “safe harbor” created by the Private Securities Litigation Reform Act of 1995. The Company’s actual results could differ significantly from those discussed and/or implied herein.

Hi-Way Equipment, a portfolio company of ComVest, acquires Equipment Support Services, Inc. of Houston.

The combined company will operate under the name of Hi-Way Equipment Company and the organization will boast eleven offices and more than 200 employees in the southeast, central and north Texas areas. The combined company offers a broad range of premier brands of new and used construction, road building, paving, utility and agricultural equipment, complete parts and service capabilities and an extensive line of rental equipment to its customers in the dynamic southeast and north Texas markets.

Hi-Way’s presence in the Houston and southeast Texas market dates to 1948, while ESS has served southeast, central and north Texas customers since 1999. Among its premier brands, the combined Company offers equipment from Case CE, Case IH, Gradall, Wirtgen, Hamm, Vögele, Kawasaki, LeeBoy, Rosco, Pettibone, Vacall and Allianz- Madvac/Johnston.

Serving central and southeast Texas, the Company has three offices in the Houston area (near Intercontinental and Hobby airports and in Alvin), and locations in Beaumont, Bryan, Brenham. In North Texas, Company locations are in Euless (near DFW airport and serving Dallas and Ft. Worth), Sherman, Gainesville, Longview and Tyler. Each of the eleven offices carries a complete inventory of parts, provides a full range of service capability and offers an extensive rental fleet – all supported by an experienced and professional staff.

Bryan Monk and Kyle Foley of ESS and Dan Blade of Hi-Way will lead the new company’s operations. Dan will be responsible for the company’s extensive southeast Texas operations (Houston and Beaumont), Kyle will assume responsibility for the north Texas stores (Euless, Sherman, Gainesville, Longview and Tyler) and Bryan will oversee operations in Bryan and Brenham as well as assume responsibility for most corporate level functions.

You can reach us at any of the Hi-Way or Equipment Support Services phone numbers or at our websites www.hi-wayequipment.com or www.esscorp.com.

West Palm Beach, Florida, December 2008 – The ComVest Group, through ComVest Investment Partners III, LP., has made an investment in a newly formed company to acquire, through a section 363 bankruptcy sale, certain assets of TWL Corporation. The Company, based in Carrollton, Texas, provides its content to approximately 2,000 clients and owns one of the largest content libraries for training and certification. The investment represents an opportunity to partner with Norm Willox, who for over five years was the Chief Business Officer of LexisNexis Risk Information and Analytics and was most recently Chief Executive Officer of LexisNexis Special Services. Previously Mr. Willox founded and built several information technology companies in the risk management sector. During this period of time, Mr. Willox was the principal shareholder and CEO of the National Fraud Center for over ten years and a board member and officer of Riskwise International. Mr. Willox is considered a leading executive in developing and providing data / technology services for risk assessment. Mr. Willox brings a strong and experienced team of executives who he has worked with for over twenty years.

About TWL Corporation
TWL Corporation, based in Carrollton, Texas, is a technology-enabled learning and certification solutions provider for corporations, government organizations, and individuals. The company sells its content to clients to train, educate, and certify employees in the areas of state and federal regulatory compliance, ongoing job certification, continuing education and risk mitigation.

About ComVest
The ComVest Group is a leading investment firm focused on investing in middle-market companies in a debt or equity capacity. Since 1988 ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders.

The ComVest Group, through its Debt Fund, ComVest Capital, has provided $10 million in financing to Rave LLC, a leading supplier of advanced process solutions to the Semiconductor and Photomask Industries. The financing was structured as a $6 million senior working capital revolver and a $4 million purchase order finance line.
About RAVE LLC
Since 2001, RAVE has been recognized as the industry leader in advanced photomask repair with products that include high-speed laser and precision nanomachining systems designed for the accurate removal of defects on >=32nm photomasks. With the introduction of the new Rhazer™ Haze Removal System, RAVE is once again pioneering another breakthrough in advanced equipment technology that is expected to bring enormous cost savings to Semiconductor wafer fabricators around the World.

The ComVest Group has invested $20.3 million in AirTran Holdings (NYSE: AAI), a leading low fare airline headquartered in Orlando, Florida. The investment was made in the form of a $3.5 million Convertible Term Note and $16.8 million in Common Equity. AirTran is one of the largest airlines in the United States in terms of departures and seats offered. The Company operates 87 Boeing B717s and 50 Boeing B737 aircraft offering approximately 700 scheduled flights per day to 55 locations within the United States.

The ComVest Group (“ComVest”), a leading West Pam Beach based private investment firm announced today that it has successfully raised $335 Million on behalf of ComVest Investment Partners III, L.P. (the “Partnership” or “ComVest III”). The Partnership held its final closing on May 30, 2008, with aggregate commitments totaling $335 million. The Limited Partners of ComVest III are comprised of domestic and international investors representing public and private pensions, insurance companies, fund of funds, family offices, and high net worth individuals.

To date the General Partner on behalf of ComVest III has deployed $85 Million in five transactions for the Partnership. ComVest III is focused on continuing ComVest’s expertise of making investments in small to mid size businesses that are well positioned to become industry leaders. The ComVest Group has a significant amount of investment experience within the software and technology, healthcare, aviation, transportation and logistics, and manufacturing sectors; despite a history of excellence in these sectors, the firm’s vast relationships with successful operating executives allows for effective evaluation of opportunities across a myriad of industries.

ComVest Co-founder and managing partner Michael Falk said, “ComVest pairs seasoned deal teams capable of sourcing, evaluating, and structuring transactions with an expansive network of operating partners. Together with our operating partners ComVest seeks to provide operating improvements and strategic guidance to portfolio companies. ComVest provides portfolio companies with an operating experience that enables us to invest in healthy or distressed businesses in favorable or out of favor sectors as well as across a variety of special situations”.

West Palm Beach, Florida, December 2007 – The ComVest Group has acquired Southern Comfort Conversions (“Southern Comfort”). The largest vehicle converter in the United States, the Company has both strategic alliances with automobile manufacturers, particularly General Motors, and a large dealer distribution network. Through its alliance with GM, the Company has recently secured exclusive contracts to produce Special Edition Hummers and customized Cadillac Escalades. ComVest anticipates the company is well positioned for significant growth.

About Southern Comfort
Southern Comfort is a vertically integrated manufacturer and chassis converter for General Motors, Ford and Dodge. Southern Comfort is the largest automobile aftermarket up-fitter in the United States and provides specialty manufacturing services to the marine, motor home and golf industries. The Company provides a superior and unique paint job to standard vehicles off the assembly line, and creates custom lighting, proprietary ground effects and wheels, and an attractive interior finish. This customized look creates a very appealing and distinct product for dealers who are increasingly looking for differentiation as a competitive edge in the marketplace and allows dealers the opportunity to close higher margin sales. For more information please visit www.scomfort.com.

About ComVest
The ComVest Group is a leading investment firm focused on investing in middle-market companies in a debt or equity capacity. Since 1988 ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

West Palm Beach, Fl., November 1, 2007 – ComVest’s portfolio company, Averion International Corp. (OTC:AVRO) (“Averion”), today announced that it has acquired Hesperion AG (“Hesperion”), a Swiss-based, international, full-service, clinical research organization (CRO), from its parent company, Cerep SA. The €25.0 million (approximately $36.2 million) acquisition purchase price included an upfront cash payment of €20.0 million ($29.0 million) with an additional €5.0 million (approximately $7.2 million) to be paid within thirty days through the issuance of a promissory note. With the completion of this acquisition, Averion now has 14 offices in 10 countries, a significantly strengthened presence in Europe, and has doubled its full-time employee base to approximately 400.

Averion today also announced that it has completed a senior secured debt financing, raising gross proceeds of $24.0 million to fund the acquisition through the issuance of three-year senior secured notes. The Company will also receive additional gross proceeds of $2.0 million within thirty days after the initial closing on the same terms, resulting in aggregate gross proceeds of $26 million to the Company from both closings. At such time as the additional $2.0 million in notes are purchased, the purchasers will also be issued an additional 9,600,000 shares of common stock. Collins Stewart LLC and Commonwealth Associates acted as co-placement agents and Jefferies & Company, Inc. acted as co-advisors for the transaction.

Philip T. Lavin, PhD, formerly Averion’s Chief Executive Officer, has been named to the newly created position of Executive Chairman. Markus H. Weissbach, MD, PhD, Hesperion’s CEO, has been appointed CEO of Averion and will relocate to the Company’s U.S. headquarters. Dr. Weissbach brings to Averion more than 18 years of clinical research management experience in the pharmaceutical industry. Chris Codeanne remains in his current capacity as Averion’s Chief Financial Officer. Averion will continue to be headquartered in Southborough, Massachusetts with its European base of operations in Basel, Switzerland.

“The acquisition of Hesperion, a high quality European CRO, represents an ideal strategic fit with Averion’s U.S. centric business and approximately doubles the size of our Company. Both companies bring extensive long-term client relationships to the combined organization and have each been independently experiencing impressive organic growth. The combination creates a mid-size global CRO capable of managing complex larger global clinical trials for its clients,” said Michael Falk, Chairman of Averion’s Board of Directors.

“Current CRO industry trends indicate a growing need for the ability to perform larger, full-service global trials. With this transaction, we enhance our competitive position by doubling the size of our operations and broadening our client base,” said Dr. Lavin. “We have the capabilities to span the CRO lifecycle from first-in-man clinical trials through marketing authorization and into post-market surveillance and reimbursement. Averion now has the operational capacity necessary to compete for global clinical programs.”

“Hesperion has outperformed the CRO sector, achieving more than 20% annual growth over the last three years,” said Dr. Weissbach. “With this transaction, the new Averion will be more competitive in the CRO market. We share a commitment to provide critical thinking and quality processes that are necessary for the development of strong customer partnerships. We believe the acquisition will allow us to expand the depth and breadth of quality services we provide to our clients.”

About Hesperion

Founded in 1996, Hesperion has extensive experience and expertise in cardiology and oncology. Hesperion has focused on establishing clinical development partnerships with medical device, biotech and pharmaceutical companies and has employed clinical research professionals worldwide with expertise in medical and regulatory affairs, clinical operations, data management and statistics. Hesperion has conducted more than 220 projects involving 41,000 subjects in 40 countries for more than 110 clients, and it has been successfully audited by EMEA and FDA for its work on the pivotal studies of Tracleer®, the breakthrough orphan treatment for pulmonary arterial hypertension developed by Actelion Ltd.

About Averion International Corp.

Averion International Corp. is a full service clinical research organization (CRO) that provides clinical research services to the pharmaceutical, biotechnology and medical device/diagnostic industries. The Company has a therapeutic focus in oncology, medical devices, dermatology and nephrology. Averion’s core competencies are in FDA and product registration support, site selection, project management, medical and site monitoring, data management, biometrics, pharmacovigilance, medical writing, and full clinical trial management services throughout the clinical trials lifecycle. The Company has supported FDA approvals for products in many therapeutic areas including: oncology, medical devices, dermatology, and nephrology.

Averion is headquartered in Southborough, Mass. with European operations based in Basel, Switzerland. Averion has additional U.S. offices in California, Maryland and New York; and additional European offices in Austria, France, Germany, The Netherlands, Poland, Russia, and the United Kingdom; a location in Israel; and partnerships in Hungary, India and South America. For more information, visit www.averionintl.com.

About Cerep

Cerep’s mission is to provide pharmaceutical companies with high quality services in drug discovery and drug development. Cerep provides solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep has developed a unique know-how based on technologies of in vitro screening and profiling using its proprietary database BioPrint®, which allows the modeling of clinical effects of drug candidates from their molecular properties.

Cerep’s technologies benefit more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.

Over the past years, Cerep also developed a pipeline of drug candidates which includes collaborative products developed with Sanofi-Aventis and Bristol-Myers Squibb, as well as proprietary compounds (including one compound in phase I/II clinical trial in the field of cancer). These programs and associated compounds are either partnered or being licensed-out.

About ComVest
The ComVest Group is a leading Private Equity firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

Included in this release are “forward-looking statements.” Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company’s actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission, including its most recent 10-KSB. The Company is not under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.